Peripheral blood granulocyte-macrophage progenitors in patients with the myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology

Background:

• Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
• Characterized by ineffective hematopoiesis and a high risk of transformation to acute myeloid leukemia.
• Assessing progenitor cell function is crucial for understanding MDS pathogenesis and prognosis.

Purpose of the Study:

• To evaluate peripheral blood (PB) granulocyte-macrophage progenitor (CFU-GM) growth in normal subjects and MDS patients.
• To correlate PB CFU-GM growth with bone marrow (BM) CFU-GM and blast cell counts in newly diagnosed MDS.
• To determine the prognostic significance of PB CFU-GM growth in MDS.

Main Methods:

• Colony-forming unit-granulocyte-macrophage (CFU-GM) assays were performed on peripheral blood from 47 normal individuals.
• PB and bone marrow (BM) CFU-GM and blast cell counts were assessed in 45 newly diagnosed MDS patients.
• Statistical analysis was used to correlate progenitor growth with clinical parameters.

Main Results:

• MDS patients exhibited significantly reduced numbers of both PB colony and cluster growth compared to normal subjects.
• A negative correlation was observed between marrow blast cell percentage and PB colony growth in MDS patients with >5% blasts.
• PB and BM CFU-GM growth demonstrated a strong correlation in this patient subgroup.

Conclusions:

• Peripheral blood CFU-GM growth is significantly impaired in patients with myelodysplastic syndromes.
• Reduced PB CFU-GM growth shows a stronger association with prognosis in MDS than bone marrow progenitor growth.
• PB CFU-GM assays may serve as a valuable, accessible tool for prognostic assessment in MDS.